Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akari Therapeutics (NAS:AKTX) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Akari Therapeutics Effective Interest Rate on Debt % Related Terms
Akari Therapeutics Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Akari Therapeutics's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akari Therapeutics Effective Interest Rate on Debt % Chart
AKTX vs MBRX, INTI, TPST: Effective Interest Rate on Debt % Comparison
For the Biotechnology subindustry, Akari Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akari Therapeutics Effective Interest Rate on Debt % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Akari Therapeutics's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 32.84% mean?
Akari Therapeutics (AKTX) has a Effective Interest Rate on Debt % of 32.84% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Akari Therapeutics and its competitors.
Is Akari Therapeutics' Effective Interest Rate on Debt % too high?
Akari Therapeutics' current Effective Interest Rate on Debt % is 32.84%. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' Effective Interest Rate on Debt % compare to MBRX and INTI?
Akari Therapeutics' Effective Interest Rate on Debt % of 32.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Akari Therapeutics and its competitors. Akari Therapeutics's current Effective Interest Rate on Debt % is 32.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (AKTX) has a current Effective Interest Rate on Debt % of 32.84%. The current Effective Interest Rate on Debt % is 32.84%. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current Effective Interest Rate on Debt % is 32.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score
Get the complete analysis for AKTX
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTX has been successfully added to your 
